Intraocular inflammation and presumed retinal vasculitis following initial pegcetacoplan intravitreal injection

Main Article Content

Josephine R. Seela, MD
Talhah Zubair, MD
Tommaso Vagaggini, MD
David F. Williams, MD

Abstract

We report a case of presumed retinal vasculitis and precipitous complete vision loss following a single intravitreal injection of pegcetacoplan. A 76-year-old woman received intravitreal pegcetacoplan in the right eye for geographic atrophy. Visual acuity was 20/50 right eye. Ten days after the injection, she experienced initial signs of subjective vision loss. On day 11, she presented with elevated intraocular pressure and visual acuity of hand motions, worsening to no light perception (NLP) by day 12. Anterior chamber and vitreous fluid taps for Gram stain and culture were negative. On day 22, the patient had diffuse retinal hemorrhages along a retinal vascular distribution. At day 83, visual acuity remained NLP. This patient developed presumed occlusive retinal vasculitis, progressing from visual acuity of 20/50 to NLP within 2 days of initial subjective vision loss and 12 days of a single intravitreal pegcetacoplan injection.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Seela JR, Zubair T, Vagaggini T, Williams DF. Intraocular inflammation and presumed retinal vasculitis following initial pegcetacoplan intravitreal injection. Digit J Ophthalmol. 2026;32(2). doi:10.5693.djo.02.2026.02.001
Section
Case Reports

References

Heier JS, Lad EM, Holz FG, et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 2023;402:1434-48.

Witkin AJ, Jaffe GJ, Srivastava S.K, Davis JL, Kim JE. Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee. J Vitreoretin Dis 2023;8:9-20.

Nahar A, Eliott D, Avery RL, et al. Retinal vasculopathy and choroiditis after pegcetacoplan injection: clinicopathologic support for a drug hypersensitivity reaction. Ophthalmol Retina 2025;9:352-66.

Apellis announces 24-month results showing increased effects over time with pegcetacoplan in phase 3 derby and oaks studies in geographic atrophy (GA) 2022. https://investors.apellis.com/news-releases/news-release-details/apellis-announces-24-month-results-showing-increased-effects.